This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Simplifying the Prior Authorization Process to Improve IBD Patients' Access to Biologics

Simplifying the Prior Authorization Process to Improve IBD Patients' Access to Biologics

Format

Webcast

Time to Complete

1 hour

Released

February 27, 2018

Expires

February 27, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM
1.00 / CNE Contact Hour

Accredited Provider



Provided by Postgraduate Institute for Medicine

In collaboration with



In collaboration with MedInsights CE Academy

Commercial Supporter

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Program Description

Almost 60% of GI providers have had a patient’s biologic treatment switched due to insurance rules. Prior authorization barriers often restrict patients' access to therapy. Don't let this happen to your patients.

Intended Audience

This activity is intended for registered nurses, nurse practitioners and physician assistants, and other members of the clinical care team engaged in the care of patients with Inflammatory Bowel Disease (IBD).

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe real-world ways to reduce time spent on prior authorizations for biologic therapies used for patients with moderate to severe IBD.
  • Explain how to establish a protocol to consistently document data required for prior authorizations and communicate it more effectively to payers.
  • List the different ways practices can use to complete PAs, as well as the pros and cons of methods including NCPDP ePA transactions, payer portals and secure emails.
  • List tools and resources that can improve provider/payer relationships and simplify the prior authorization and appeals process for GI practices.
  • Identify situations where a biologic drug should be considered early and discuss supporting evidence for appeals letters.

Conflict Of Interest Disclosure Policy

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Joseph D. Feuerstein, MD
Attending in Gastroenterology
Center for Inflammatory Bowel Disease
Beth Israel Deaconess Medical Center
Assistant Professor of Medicine, Harvard Medical School

Joseph Feuerstein, MD, has nothing to disclose.
Laurie Powers Yopp, RN
IBD Nurse Coordinator, Division of Gastroenterology
UNC Multidisciplinary IBD Center

Laurie Powers Yopp, RN, discloses the following:
Consulting Fees: Merck
Fees for Non-CME Services Received Directly from a Commercial Interest: Takeda

Accredited Provider Disclosures

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

Publishing Staff disclosures

The following MedInsights CE Academy planners and managers, Kristen Holstead and Laurette Ullian, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medical Logix, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

1.00

Type

CNE Contact Hour(s)

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medical Logix, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.

For information about the accreditation of this program, please contact Postgraduate Institute for Medicine at: information@pimed.com or (303) 799-1930.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue